EcoR1 Capital — Full Portfolio

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.

BiotechHealthtechMedical DevicesThousand Oaks, US

Co-investorsDag VenturesHEALTHCARE ROYALTY PARTNERSKleiner Perkins

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)

BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCardinal PartnersSofinnova VenturesDomain PartnersPolaris PartnersSamsara BioCapital

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)in

BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)inDavid Hirsch(Director)

Co-investorsAPERTURE Venture PartnersFrazier Life SciencesLongitude Capital

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Director)Ryan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inCarole Ho(Executive Officer)Steve E. Krognes(Director)

BoardDavid P. Schenkein(Director)in

Co-investorsARCH Venture PartnersF-Prime CapitalForesite CapitalGV (Google Ventures)

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

Feng Zhang(Scientific Founder, Core Member, Broad Institute of MIT and Harvard)George Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in

Co-investorsSofinnova Ventures

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in

BoardStuart Lawson(Director)

Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+8 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Joshua Bilenker, M.D.(Director)

Co-investorsARCH Venture PartnersBay City CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapital

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsage1Atlas VentureAvoro Capital AdvisorsForesite Capital

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inHEIDI HENSON(Executive Officer)inANNETTE NORTH(Executive Officer)

Co-investorsARCH Venture PartnersAvoro Capital AdvisorsForesite CapitalNextech InvestOUP (Osage University Partners)

Neurogene develops gene therapy treatments for rare neurological diseases.

BiotechDeep TechDigital HealthLongevityMedical Devices

Rachel McMinn(Founder and Chief Executive Officer)Rachel McMinn, Ph.D.(Founder and Chief Executive Officer)

Nuvation Bio is a global oncology company developing and commercializing novel therapies for difficult-to-treat cancers, targeting indications where conventional treatments have failed.

BiotechHealthtechNew York, US

David Hung(Founder, President & Chief Executive Officer)

Co-investorsAisling CapitalDecheng CapitalVertex Ventures ChinaOmega Funds

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

Richard Heyman(Chairman, Founder, Scientific Advisory Board)Charles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Jacob M. Chacko(Executive Officer, Director)inDominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)in

Co-investorsNew Enterprise Associates (NEA)Nextech InvestTaiho Ventures, LLCThe Column Group

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)

BoardKristina Burow(Director)inAmir Nashat(Director)inKatrine Bosley(Director)Michael Gilman(Director)

Co-investorsAisling CapitalARCH Venture PartnersPolaris Partners

Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases.

BiotechAustin, US

Josiah Hornblower(President/CEO)in

BoardWalter Loewenbaum(Director)

Co-investorsHatteras Venture PartnersOrbiMedT. Rowe Price

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in

Co-investorsARCH Venture PartnersSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation EndeavorsLeaps by Bayer+5 more

Epikast provides AI-powered tools for medical science liaisons and field teams to analyze clinical interactions with physicians and patients, and to access synthesized scientific information in their disease areas.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBrooklyn, US

Evangelos Vergetis(Executive Officer, Director)

BoardBrad Prosek(Director)Stelios Papadopoulos(Director)Daphne Karydas(Director)Alexandros Tzoukas(Director)

Board seatOleg Nodelman· per SEC Form D

Co-investorsVedanta Capital

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Board seatOleg Nodelman· per SEC Form D

Co-investorsAju IB Invesment CorporationEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)Pfizer Venture Investments+6 more

BiotechBoston, US

Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)

Board seatOleg Nodelman· per SEC Form D

Co-investorsAtlas VentureAvoro Capital AdvisorsFrazier Life SciencesNextech InvestVida VenturesLightspeed Venture Partners+2 more

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsAtlas VentureDroia VenturesGV (Google Ventures)The Column GroupJJDCJohnson & Johnson Innovation – JJDC+1 more

Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions.

BiotechDeep Tech

David Breckenridge(Founder)in

Co-investorsCanaan Partners

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)

Co-investorsAtlas VentureEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover+1 more

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBain Capital Life SciencesForesite Capital

Ajax Systems produces wired and wireless intrusion protection devices for professional security installations, offered through two product lines: Baseline for general projects and Ajax Superior for advanced, high-security applications that require partner accreditation and training.

AI & Machine LearningCybersecurityEnterprise SoftwareHardwareIoT

Co-investorsEndeavor CatalystHorizon Capital

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(Co-founder & Board Member)Ross Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsInning One VenturesVivo Capital

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in

BoardEd Mathers(Director)inKush Parmar(Director)in

Co-investors5AM VenturesNew Enterprise Associates (NEA)RA CapitalSofinnova VenturesCowen Healthcare InvestmentsFidelity Investments+1 more

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing retinal disease treatments, specifically engineered biologics for wet AMD, diabetic eye disease, and retinal vein occlusion.

BiotechDigital HealthMedical DevicesBerkeley Heights, US

Napoleone Ferrara(Director & Co-Founder)Srinivas Akkaraju(Director & Co-founder)Mike Dybbs(Director & Co-founder)

A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.

BiotechDigital HealthHealthtechMedical DevicesMental HealthIndianapolis, US

Jaswant Gidda(Executive Officer, Director)James Schulz(Executive Officer)Yvonne Lai(Executive Officer)

BoardNora Doherty(Director)Derek Small(Director)Anantha Shekhar(Director)

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling CapitalDecheng CapitalDroia VenturesForesite CapitalSLVCSofinnova Ventures+2 more

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.

BiotechHealthtechMedical DevicesSan Diego, US

Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in

Co-investors5AM VenturesRA CapitalvenBio PartnersvenBio Global Strategic

BiotechRedwood City, US

William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)

BoardBrian Atwood(Director)Franklin Berger(Director)

Co-investorsAisling CapitalMission Bay CapitalMission Biocapital

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

Zaneta Odrowaz(Founder)in

Co-investorsFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesVida VenturesGoldman Sachs

AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases.

BiotechDigital HealthHealthtechMedical Devices

George Montgomery(Executive Chairman)

Co-investorsEvolution VC PartnersHelios CapitalPlum Alley InvestmentsSocii CapitalTribe Capital Firstlook

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.

BiotechHealthtech

Co-investorsAisling CapitalAmzak HealthFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSLongwood FundSequoia Capital

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.

Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US

Fabian Gerlinghaus(Co-Founder and Chief Executive Officer)inOmar Kurdi(Co-Founder and President)in

BoardJustin Butler(Director)inVictor Tong(Director)in

Co-investorsDecheng Capital8VCIntuitive VenturesKoch Disruptive TechnologiesBaillie GiffordBlackRock+4 more

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsAdvent Life SciencesForesite CapitalMedicxiOberland CapitalScion Life SciencesVida Ventures+1 more

Co-investorsRA Capital

Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.

BiotechSeattle, US

Doug Williams(Executive Officer, Director)

BoardNoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)

Co-investorsARCH Venture PartnersFlagship Pioneering

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Co-investorsAtlas VentureFrazier Life SciencesSanofi Ventures

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.

BiotechDeep TechHealthtechWaltham, US

David Hallal(CEO)Mike Paglia(Chief Technology Officer)Ger Brophy(CEO)

Co-investorsMPM BioImpactSamsara BioCapitalSoftBank Vision Fund

Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.

BiotechDigital HealthHealthtechMedical Devices

Dr. Rod MacKinnon(Founder)

Co-investorsBessemer Venture PartnersLightstone VenturesLongwood Fund

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsGV (Google Ventures)Nextech InvestVida Ventures

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)inLynn Yang(Director)

BoardCarl Gordon(Director)in

Co-investorsOrbiMedRoche Venture Fund

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in

Co-investorsage1LAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more

HealthtechWest Lafayette, US

Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)Ronald Martell(Director)Franklyn Prendergast, M.D., Ph.D.(Director)

Co-investorsArsenal Bridge Venture

Co-investorsAisling CapitalLongitude Capital

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

BiotechEvanston, US

Joseph R. Moskal(Executive Officer)Amin Khan(Executive Officer)James Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)

Co-investorsCota CapitalLatterell Venture PartnersSofinnova Ventures

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)

Co-investorsJeito CapitalVida VenturesTPG

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.

BiotechHealthtechWilmington, CN

Yan Lou(Founder)Zhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)

BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)

Co-investorsLAVLilly Asia VenturesRA CapitalSamsara BioCapitalThe Innovation SpaceLogos

Co-investorsToronto Innovation Acceleration Partners

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)Mark Goldsmith(Director)

Co-investorsBain Capital Life SciencesForesite CapitalSofinnova VenturesThe Column Group

BiotechSan Francisco, US

Jonathan Winger(Executive Officer, Director)Stephen Cary(Executive Officer, Director)

BoardJeffrey S. Samberg(Director)Laurence Marton(Director)Mitchell Mutz(Director)Jeff Samberg(Director)

Co-investorsWavemaker Three-Sixty Health

Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.

AI & Machine LearningBiotechDeep TechUnited States, US

Co-investorsARCH Venture PartnersClavystBio

BiotechMenlo Park, US

Ervin Epstein(Executive Officer, Director)Jean Tang(Director)Mark de Souza(Executive Officer)

BoardKatrin Andreasson(Director)

Co-investorsAisling Capital

Co-investorsPontifax Venture Capital

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep Tech

Sanjiv K. PatelDon BergstromTom CatinazzoMahesh PadvalImogen PrycePeter Rahmer

Co-investorsNextech InvestSoftBank Vision FundGeneral Catalyst

BiotechMedical Devices

Co-investorsARCH Venture Partners

BiotechDigital HealthMedical DevicesSeattle, US

Peter A. Thompson(Executive Officer, Director)

Co-investorsPontifax Venture CapitalRA CapitalUS Venture Partners

Co-investorsAisling CapitalAvoro Capital AdvisorsBioBritDelos Capital

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.

AI & Machine LearningBiotechMedical DevicesWatertown, US

Timothy A. Springer(Co-Founder)Andrew C. KruseTimothy Springer(Director)Andrew Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)

Co-investorsVida VenturesAlly Bridge GroupClarusPolaris PartnersSoleus Capital

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)

BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)

Co-investorsOrbiMedRA CapitalNovo HoldingsOsage University PartnersThird Rock Ventures

Co-investorsHorizons VenturesLux CapitalTCG CrossoverThe Column GroupInnovation Endeavors

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsage1ARCH Venture PartnersCycad Group LLCKhosla VenturesVenrock

Co-investorsPfizer Venture Investments